Maternal serum CA 19-9 and CA 15-3 levels in pregnancies affected by trisomy 21

Prenatal Diagnosis

Volumn 32, Issue 7, 2012, Pages 644-648

  Akinlade, F ^a   Cowans, N J ^a   Kisanga, M C ^a   Spencer, K ^a  

^a KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; BODY WEIGHT; CASE CONTROL STUDY; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MATERNAL AGE; MATERNAL SERUM; MONTE CARLO METHOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRISOMY 21;

ADULT; BIOLOGICAL MARKERS; BODY WEIGHT; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMANS; MUCIN-1; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES;

EID: 84863499655     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.3875     Document Type: Article

References (33)

1. Spencer K, Spencer CE, Power M, et al. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: A review of three years prospective experience. BJOG 2003 Mar;110(3):281-6.
2. Nicolaides KH, Spencer K, Avgidou K, et al. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: Results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005 Mar;25(3):221-6.
3. Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008 Jun;31(6):618-24.
4. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med 2011 Nov;13(11):913-20.
5. Benn P, Borrell A, Cuckle H, Dugoff L, Gross S, Johnson J-A, Maymon R, Odibo A, Schielen P, Spencer K, Wright D, Yaron Y. Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2012;32(1):1-2.
6. Koster MP, Pennings JL, Imholz S, et al. Bead-based multiplexed immunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening. Prenat Diagn 2009 Sep;29(9):857-62.
7. Kolialexi A, Tsangaris GT, Papantoniou N, et al. Application of proteomics for the identification of differentially expressed protein markers for Down syndrome in maternal plasma. Prenat Diagn 2008 Aug;28(8):691-8.
8. Nagalla SR, Canick JA, Jacob T, et al. Proteomic analysis of maternal serum in down syndrome: Identification of novel protein biomarkers. J Proteome Res 2007 Apr;6(4):1245-57.
9. Koster MP, Pennings JL, Imholz S, et al. Proteomics and Down syndrome screening: A validation study. Prenat Diagn 2010 Nov;30(11):1039-43.
10. Mastricci AL, Akolekar R, Kuppusamy R, et al. Are serum protein biomarkers derived from proteomic analysis useful in screening for trisomy 21 at 11-13weeks? Fetal Diagn Ther 2011;30(1):53-9.
11. Koster MPH. Innovations in Down syndrome screening (thesis). 2010.
12. Spencer K. Maternal serum CA125 is not a second trimester marker for Down's syndrome. Ann Clin Biochem 1991 May;28 (Pt 3):299-300.
13. Spencer K, Muller F, Aitken DA. Amniotic fluid and maternal serum levels of CA125 in pregnancies affected by Down syndrome: A re-evaluation of the role of CA125 in Down syndrome screening. Prenat Diagn 1997 Aug;17(8):701-6.
14. Spencer K, Carpenter P. Is prostate-specific antigen a marker for pregnancies affected by Down syndrome? Clin Chem 1998 Nov;44(11):2362-5.
15. Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002;9(1):2-6.
16. Cuckle HS, Benn PA. Multi-marker maternal serum screening for chromosomal abnormalities. In Genetic Disorders and the Fetus (6th edn), Milunsky A, Mulunsky J (eds). Blackwell Publishing, 2010; 771-818.
17. Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: The results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7(11):1-77.
18. Botsis D, Sarandakou A, Kassanos D, et al. Breast cancer markers during normal pregnancy. Anticancer Res 1999 Jul;19(4C):3539-41.
19. Lelle RJ, Henkel E, Leinemann D, et al. Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest 1989;27(3):137-42.
20. Schrocksnadel H, Daxenbichler G, Artner E, et al. Tumor markers in hypertensive disorders of pregnancy. Gynecol Obstet Invest 1993;35(4):204-8.
21. Bon GG, Kenemans P, Verstraeten AA, et al. Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy. Fetal Diagn Ther 2001 May;16(3):166-72.
22. Cheli CD, Morris DL, Neaman IE, et al. Measurement of four tumor marker antigens in the sera of pregnant women. J Clin Lab Anal 1999;13(1):35-9.
23. Schlageter MH, Larghero J, Cassinat B, et al. Serum carcinoembryonic antigen, cancer antigen 125, cancer antigen 15-3, squamous cell carcinoma, and tumor-associated trypsin inhibitor concentrations during healthy pregnancy. Clin Chem 1998 Sep;44(9):1995-8.
24. Touitou Y, Darbois Y, Bogdan A, et al. Tumour marker antigens during menses and pregnancy. Br J Cancer 1989 Sep;60(3):419-20.
25. Ercan S, Kaymaz O, Yucel N, et al. Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study. Arch Gynecol Obstet 2011 Jul 27.
26. Noci I, Borri P, Biagiotti R, et al. Amniotic fluid levels of CA 19.9 and CA 15.3 in normal and Down's syndrome pregnancies. J Perinat Med 1995;23(3):237-41.
27. Hohlfeld P, Dang TT, Nahoul K, et al. Tumour-associated antigens in maternal and fetal blood. Prenat Diagn 1994 Oct;14(10):907-12.
28. Huber LA. Is proteomics heading in the wrong direction? Nat Rev Mol Cell Biol 2003 Jan;4(1):74-80.
29. Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002 Nov;1(11):845-67.
30. Silberring J, Ciborowski P. Biomarker discovery and clinical proteomics. Trends Analyt Chem 2010 Feb 1;29(2):128.
31. Tambor V, Fucikova A, Lenco J, et al. Application of proteomics in biomarker discovery: A primer for the clinician. Physiol Res 2010;59(4):471-97.
32. Garbis S, Lubec G, Fountoulakis M. Limitations of current proteomics technologies. J Chromatogr A 2005 Jun 3;1077(1):1-18.
33. Petrak J, Ivanek R, Toman O, et al. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008 May;8(9):1744-9.